Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 8/20 | 0.62 |
| ▸ | MME | P08473 | 3/20 | 0.60 |
| ▸ | CTSG | P08311 | 1/20 | 0.58 |
| ▸ | CMA1 | P23946 | 1/20 | 0.58 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | CPA1 | P15085 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.55 |
| ▸ | FPR2 | P25090 | 1/20 | 0.55 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | ECE1 | P42892 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28952171 | 1.00 | ACE (0.62) | ACEMMECTSGCMA1NAALAD2 | |
| SCHEMBL987963 | 0.87 | FAAH (0.64) | ACEMMENAALAD2NPSR1CPA1 | |
| SCHEMBL265066 | 0.87 | FAAH (0.64) | ACEMMENAALAD2NPSR1CPA1 | |
| SCHEMBL11793269 | 0.87 | FAAH (0.64) | ACEMMENAALAD2NPSR1CPA1 | |
| SCHEMBL2806565 | 0.87 | FAAH (0.67) | ACECTSGCMA1NAALAD2FAAH | |
| SCHEMBL995229 | 0.87 | ALDH1A1 (0.64) | ACEMMECTSGCMA1NAALAD2 | |
| SCHEMBL2806570 | 0.87 | FAAH (0.67) | ACECTSGCMA1NAALAD2FAAH | |
| SCHEMBL6293500 | 0.87 | ALDH1A1 (0.64) | ACEMMECTSGCMA1NAALAD2 | |
| SCHEMBL995228 | 0.87 | ALDH1A1 (0.64) | ACEMMECTSGCMA1NAALAD2 | |
| SCHEMBL23227492 | 0.85 | ACE (0.63) | ACEMMENAALAD2NPSR1CPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030228285-A1 | Bipartite T-cell factor (Tcf)-responsive promoter | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-12-11 | — | — | US | claimed |
| US-20250345409-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | GENVIVO INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12350327-B2 | Compositions and methods for therapeutic or vaccine delivery | Genvivo, Inc. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250115930-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC DELIVERY | Genvivo, Inc. | 2025-04-10 | — | — | US | disclosed |
| US-12234475-B2 | Compositions and methods for therapeutic delivery | Genvivo, Inc. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250032582-A1 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | MURAL ONCOLOGY, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| US-20250000938-A1 | Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy | MURAL ONCOLOGY, INC. (US) | 2025-01-02 | — | — | US | disclosed |
| EP-4475865-A2 | COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY | Mural Oncology, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| US-20240366746-A1 | COMPOSITIONS AND METHODS FOR THERAPEUTIC OR VACCINE DELIVERY | Genvivo, Inc. | 2024-11-07 | — | — | US | disclosed |
| CN-118891055-A | Compositions and methods for cancer immunotherapy | 穆拉肿瘤公司 | 2024-11-01 | — | — | CN | disclosed |
| EP-1501861-A4 | TARGETING PROTEINS TO DELIVER THERAPEUTIC OR DIAGNOSTIC REAGENTS | UNIV TEXAS (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070134206-A1 | TARGETING PROTEINS TO DELIVER THERAPEUTIC OR DIAGNOSTIC REAGENTS | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2007-06-14 | — | — | US | disclosed |
| EP-1619951-A2 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | Epeius Biotechnologies, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1501861-A1 | TARGETING PROTEINS TO DELIVER THERAPEUTIC OR DIAGNOSTIC REAGENTS | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20040253215-A1 | Methods and compositions for treating disorders | Genvivo, Inc. | 2004-12-16 | — | — | US | disclosed |
| WO-2004093810-A2 | METHODS AND COMPOSITIONS FOR TREATING DISORDERS | EPEIUS BIOTECHNOLOGIES, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
| US-20040005684-A1 | Targeting proteins to deliver therapeutic or diagnostic reagents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2004-01-08 | — | — | US | disclosed |
| US-20030228285-A1 | Bipartite T-cell factor (Tcf)-responsive promoter | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-12-11 | — | — | US | disclosed |
| WO-2003093303-A1 | TARGETING PROTEINS TO DELIVER THERAPEUTIC OR DIAGNOSTIC REAGENTS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-1991005555-A2 | N-ACYL PEPTIDE METALLOENDOPEPTIDASE INHIBITORS AND METHODS OF USING SAME | THE SALK INSTITUTE BIOTECHNOLOGY/INDUSTRIAL ASSOCIATES, INC. (US) | 1991-05-02 | — | — | WO | disclosed |